Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
- Conditions
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1473
- Registration Number
- NCT01953588
- Locations
- 🇺🇸
Mercy Medical Center, Springfield, Massachusetts, United States
🇺🇸Southwest Oncology PC, Durango, Colorado, United States
🇺🇸Epic Care-Dublin, Dublin, California, United States
Impact of Estradiol Addback
- Conditions
- Interventions
- First Posted Date
- 2013-05-27
- Last Posted Date
- 2019-06-07
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 43
- Registration Number
- NCT01862835
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
- Conditions
- Interventions
- First Posted Date
- 2013-04-05
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 1046
- Registration Number
- NCT01824836
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
🇺🇸Veterans Adminstration New Jersey Health Care System, East Orange, New Jersey, United States
Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT01814397
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-01-25
- Last Posted Date
- 2018-05-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 16
- Registration Number
- NCT01776008
- Locations
- 🇺🇸
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Study of the Effect of Testosterone and Estradiol on NP Responses to Acute and Chronic Salt Loading
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT01763541
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-11-08
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 84
- Registration Number
- NCT01723774
- Locations
- 🇺🇸
Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic - Rochester, Rochester, Minnesota, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-11-02
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 15
- Registration Number
- NCT01720602
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1939
- Registration Number
- NCT01674140
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Aria Health-Torresdale Campus, Philadelphia, Pennsylvania, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 101
- Registration Number
- NCT01597193
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Tennessee Oncology, PLLC., Nashville, Tennessee, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.